SCHEMBL7675265

SCHEMBL7675265

COc1ccc(CCc2[c]ccc(Oc3ccccc3)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
FFAR1 O14842 1/20 0.41
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41
TUBB8 Q3ZCM7 1/20 0.41
TUBA3E Q6PEY2 1/20 0.41
TUBA1A Q71U36 1/20 0.41
TUBA1C Q9BQE3 1/20 0.41
TUBB6 Q9BUF5 1/20 0.41
TUBB2B Q9BVA1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7675262 0.84 ABCB1 (0.54) FFAR1ABCB1MEN1KMT2AMAOB
SCHEMBL8125802 0.82 LTA4H (0.43) LTA4HKDM4EALDH1A1SMN1; SMN2MAOB
SCHEMBL7670255 0.79 ALDH1A1 (0.43) KDM4EALDH1A1HTTSMN1; SMN2TUBB4A
SCHEMBL7669645 0.78 MAOB (0.44) KDM4EALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL7676584 0.77 HTT (0.40) KDM4EALDH1A1HTTSMN1; SMN2TUBB4A
SCHEMBL7671780 0.77 TUBB4A (0.45) KDM4EALDH1A1TUBB4ATUBBTUBA3C
SCHEMBL7669559 0.77 MAOB (0.45) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL8480190 0.76 LTA4H (0.44) LTA4HKDM4EALDH1A1HTTMAOB
SCHEMBL8125726 0.75 LTA4H (0.49) LTA4HALDH1A1HTTKMT2A
SCHEMBL7673825 0.74 CALM1 (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6395730-B1 CARDIOVASCULAR DISORDERS ICAGEN, INC. 2002-05-28 US disclosed
US-6174908-B1 TREATING DISEASE, CONDITION, OR DISORDER WHICH RESPONDS TO INHIBITION OF POTASSIUM CHANNEL FUNCTION BY ADMINISTERING THIAZOLIDONE OR METATHIAZONONE COMPOUND, ITS SALT, AMIDE, ESTER, COMPLEX, CHELATE, HYDRATE, STEREOISOMER, METABOLITE ICAGEN, INC. 2001-01-16 US disclosed